KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Accounts Payables (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Accounts Payables data on record, last reported at $15.6 million in Q3 2025.

  • For Q3 2025, Accounts Payables rose 81.45% year-over-year to $15.6 million; the TTM value through Sep 2025 reached $15.6 million, up 81.45%, while the annual FY2024 figure was $11.6 million, 17.38% up from the prior year.
  • Accounts Payables reached $15.6 million in Q3 2025 per NKTR's latest filing, up from $14.3 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $23.7 million in Q3 2021 and bottomed at $2.6 million in Q2 2023.
  • Average Accounts Payables over 5 years is $11.6 million, with a median of $11.6 million recorded in 2024.
  • Peak YoY movement for Accounts Payables: crashed 78.79% in 2023, then soared 160.86% in 2024.
  • A 5-year view of Accounts Payables shows it stood at $9.7 million in 2021, then surged by 33.17% to $13.0 million in 2022, then decreased by 24.13% to $9.8 million in 2023, then increased by 17.38% to $11.6 million in 2024, then soared by 34.63% to $15.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accounts Payables were $15.6 million in Q3 2025, $14.3 million in Q2 2025, and $17.8 million in Q1 2025.